Diabetic foot
Drug research and approvals for diabetic foot: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 126 studies of diabetic foot are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 126
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 1
- Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot WoundsNCT07937215 · Not applicable · Cutempa Medical AG · starts Aug 20, 2026
- Continuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic…NCT07910721 · Not applicable · Solsius · starts Mar 10, 2026
- Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic…NCT07877948 · Not applicable · BREGO Life Sciences · starts Jul 22, 2025
- Measuring Plantar Pressures in Diabetic Patients With Lateral Forefoot AmputationNCT07865208 · Not reported · Nanyang Technological University · starts Nov 27, 2026
- a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy…NCT07852338 · Phase 3 · Applied Biologics, LLC · starts Oct 8, 2026
- DiaFootCare to Promote Self-Care of Diabetic Foot Ulcers in OmanNCT07815275 · Not applicable · Oman Ministry of Health · starts Oct 13, 2026
- Systemic Biochemical Signature and Functional Quality Index of Calcaneal Bone Marrow Aspirate in Adults Undergoing Foot…NCT07802106 · Not reported · Universidade Sao Francisco · starts Oct 21, 2026
- Effects of Transcutaneous Photobiomodulation on Diabetic Foot Ulcers.NCT07798960 · Phase 2 · University of Nove de Julho · starts May 12, 2026
- A Study Comparing an Investigational Wound Gel With Standard Treatment for Mild to Moderate Diabetic Foot UlcersNCT07783087 · Not applicable · Flen Health · starts Aug 10, 2026
Approved 2
- TazobactamBacterial beta-lactamase TEM inhibitor
- PiperacillinBacterial penicillin-binding protein inhibitor
Phase 3 12 of 22
- Aclerastide
- OfloxacinBacterial DNA gyrase inhibitor
- VancomycinPeptidoglycan inhibitor
- EsmololBeta-1 adrenergic receptor antagonist
- BecaplerminPlatelet-derived growth factor receptor agonist
- Nitric oxideSoluble guanylate cyclase activator
- Pirfenidone
- TraferminFibroblast growth factor receptor 2 agonist
- BemiparinCoagulation factor X inhibitor
- Pexiganan acetateCell membrane disrupting agent
- Panthenol
- Nepidermin
Phase 2 12
- GentamicinBacterial 70S ribosome inhibitor
- LevofloxacinDNA gyrase inhibitor
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- Dalteparin sodiumAntithrombin-III activator
- SonedenosonAdenosine A2a receptor agonist
- TelberminVascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist
- IsoniazidEnoyl-[acyl-carrier-protein] reductase inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- ChlorhexidineCell membrane inhibitor
- DeferoxamineIron chelating agent
- Fibrin
- Hypochlorous acid
Phase 1 or earlier 12 of 13
- CiprofloxacinBacterial DNA gyrase inhibitor
- Epoetin alfaErythropoietin receptor agonist
- PlerixaforC-X-C chemokine receptor type 4 partial agonist
- Collagenase clostridium histolyticumCollagen hydrolytic enzyme
- SelinexorExportin-1 inhibitor
- Epoetin zetaErythropoietin receptor agonist
- Ketanserin
- Fibroblast growth FACTOR-1
- Centella asiatica extract
- Plectranthus amboinicus extract
- ItraconazoleCytochrome P450 51 inhibitor
- Tobramycin70S ribosome inhibitor
How its trials ended
941 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 183 whose ending is known, 25% met their primary endpoint, 2% missed it and 73% stopped early.
- Completed, result not reported39542%
- Ongoing20722%
- Status unknown15617%
- Stopped: other or unclear616%
- Met its primary endpoint465%
- Stopped: enrollment or feasibility374%
- Stopped: sponsor or business decision263%
- Stopped: funding51%
- Missed its primary endpoint4<1%
- Stopped: lack of efficacy4<1%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jul 26, 2019 | Randomized placebo controlled parallel group trial to evaluate safety & efficacy of topical nitric oxide releasing solution (NORS) delivered as an adjunctive…Acidified sodium nitrite solution | Sanotize Research & Development Corp | Ongoing |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 24, 2006 | TygacilTigecycline | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA